teaser
A long-term study has confirmed that the Xience V everolimus eluting coronary stent remains a more beneficial coronary stent system than the Taxus paclitaxel-eluting version.
Data from the Spirit III trial of more than 1,000 patients, showed Xience V demonstrated a 45% reduction in the risk of major adverse cardiac events and a 32% reduction in the risk of target vessel failure at two years as compared to Taxus.
The two-year results were presented by Gregg W Stone, during the late-breaking clinical trials session at EuroPCR 2008.
Dr Stone, Columbia University Medical Center and chairman of the Cardiovascular Research Foundation, New York said: “Not only did Xience V clearly differentiate itself from the Taxus stent in the first year after treatment, it has now demonstrated even more positive effects at two years in the SPIRIT III trial.
He added that through clinically significant reductions in target vessel failure and major adverse cardiac events, Xience V demonstrated an even greater improvement in patient outcomes compared to Taxus at two years than at one year.
The team also saw encouraging trends for lower observed rates of late and very late stent thrombosis in Xience V-treated patients, especially in those who discontinued dual antiplatelet therapy.
Copyright © PA Business 2008
Columbia University Medical Center
